Evolutionary Tree Capital Management LLC Grows Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Key Points

• Evolutionary Tree Capital Management LLC increased its stake in Krystal Biotech by 24.7% during the 1st quarter, now holding a position valued at approximately $2.41 million.
• Insider Suma Krishnan sold 13,435 shares for a total of about $2.02 million, representing a 0.92% decrease in ownership.
• Analysts have mixed ratings on Krystal Biotech, with target prices ranging from $176.00 to $240.00, indicating a generally positive outlook with an average rating of "Buy."

Evolutionary Tree Capital Management LLC grew its stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 24.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,343 shares of the company's stock after buying an additional 2,643 shares during the period. Krystal Biotech makes up about 2.8% of Evolutionary Tree Capital Management LLC's holdings, making the stock its 16th biggest holding. Evolutionary Tree Capital Management LLC's holdings in Krystal Biotech were worth $2,406,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. LPL Financial LLC lifted its position in Krystal Biotech by 156.8% in the 4th quarter. LPL Financial LLC now owns 2,946 shares of the company's stock worth $462,000 after buying an additional 1,799 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Krystal Biotech by 18.7% in the 4th quarter. JPMorgan Chase & Co. now owns 151,835 shares of the company's stock worth $23,786,000 after acquiring an additional 23,934 shares during the last quarter. Norges Bank purchased a new stake in shares of Krystal Biotech in the 4th quarter valued at $34,391,000. Alliancebernstein L.P. boosted its position in Krystal Biotech by 4.7% during the fourth quarter. Alliancebernstein L.P. now owns 31,120 shares of the company's stock valued at $4,875,000 after buying an additional 1,400 shares during the period. Finally, OLD Mission Capital LLC purchased a new position in Krystal Biotech in the 4th quarter worth approximately $293,000. Institutional investors own 86.29% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on KRYS. Chardan Capital reiterated a "buy" rating and set a $219.00 price target on shares of Krystal Biotech in a report on Tuesday. Citigroup reiterated a "neutral" rating and issued a $166.00 price objective (down previously from $176.00) on shares of Krystal Biotech in a report on Tuesday. HC Wainwright reissued a "buy" rating and set a $240.00 target price on shares of Krystal Biotech in a research note on Friday, July 25th. Guggenheim dropped their price target on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Finally, Bank of America reduced their price objective on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a research report on Tuesday, July 22nd. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $210.22.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 13,435 shares of the firm's stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $150.30, for a total transaction of $2,019,280.50. Following the sale, the insider directly owned 1,443,276 shares of the company's stock, valued at $216,924,382.80. This trade represents a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders have sold 49,800 shares of company stock valued at $7,487,943. Corporate insiders own 13.70% of the company's stock.

Krystal Biotech Price Performance

Shares of KRYS traded up $1.63 on Friday, reaching $137.73. The company's stock had a trading volume of 162,230 shares, compared to its average volume of 333,965. The stock's 50 day simple moving average is $141.71 and its two-hundred day simple moving average is $155.45. The stock has a market capitalization of $3.99 billion, a P/E ratio of 27.99 and a beta of 0.70. Krystal Biotech, Inc. has a 12-month low of $122.80 and a 12-month high of $207.84.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, topping analysts' consensus estimates of $1.08 by $0.21. The business had revenue of $96.04 million during the quarter, compared to analyst estimates of $95.42 million. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. Analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).